The main objective of this study was to investigate whether a comprehensive selfmanagement programme, including self-treatment guidelines for exacerbations and a fitness programme, is an efficient treatment option for chronic obstructive pulmonary disease (COPD) patients. Method: We randomly allocated 248 COPD patients to either self-management (127) or usual care (121). Data on preference-based utilities (EuroQol-5D), health-related quality of life (HRQoL), health-care resource use and productivity losses associated with exacerbations were prospectively collected. Quality-adjusted life years (QALYs) were calculated. The economic analysis took the societal perspective and the observation period was one year. Results: As we observed that the groups were equally effective in terms of QALYs and HRQoL (SGRQ), we described a cost minimization analysis only. The self-management programme-specific costs amounted to 6642 per patient. In the base-case cost analysis, the incremental cost difference amounted to £838 per patient per year in favour of usual care. When only direct medical costs were included, the incremental annual cost of self-managementrelative to usual care was£ 179 per person per year. If time costs for the fitness programme were set to zero, the costs for self-management diminished to £542. Sensitivity analysis showed that these results were robust to changes in the underlying assumptions. Conclusion: We conclude that the COPE self-management programme is not an efficient treatment option for moderate to severe COPD patients who rate their HRQoL relatively high. The programme was twice as expensive as usual care and had no measurable beneficial effects on QALYs or HRQoL.
Introduction
Chronic obstructive pulmonary disease (COPD) causes considerable morbidity and mortality worldwide. The Global Burden of Disease Study ranked COPD as the 12th leading cause of morbidity and the sixth leading cause of death. ' By the year 2020, COPD is predicted to become the fifth leading cause of disability and the fourth leading cause of death.' Besides a substantial loss in health-related quality of life (HRQoL) for many patients, the disease places a large financial burden on health-care systems and society. Recently, a large-scale international survey revealed that the annual costs of caring for one COPD patient varied from $1023 in the Netherlands to $5646 in the USA. 2 Pharmacological treatment of COPD aims to control and alleviate symptoms and complications of respiratory dysfunction. Nonpharmacological treatment might be directed to teach patients how to optimally carry out the activities of daily living in the face of their physiological impairment, and has nowadays been recognized as an opportunity for the reduction of disability and handicap from the disease.3 Selfmanagement education is a form of nonpharmacological treatment aimed at teaching skills to optimally control disease, to obtain behaviour change, and to reach better coping with the disease.
Given the reality of limited health-care budgets, it is important to analyse whether the costs of introducing a comprehensive self-management programme for patients with COPD outweigh the potential subsequent savings in health-care utilization and productivity (indirect costs). Additionally, the cost consequences should be balanced against outcomes based on preference-based utilities such as quality-adjusted life years (QALYs). Because QALYs allow decisionmakers to compare health-care interventions both within and across diseases, this measure is currently recommended for all economic evaluations.4'5
The COPE self-management study was a large randomized controlled trial designed to evaluate the effectiveness of a self-management education course and a near-home fitness programme for patients with COPD above usual care.6 This programme included guidelines for self-treatment of exacerbations with oral prednisolone and/or antibiotics. The primary outcome was HRQoL measured by the St. George's Respiratory Questionnaire (SGRQ).7 The COPE self-management programme appeared to have no significant effect on HRQoL, both over time within the intervention group, 6 and in comparison to usual care. Furthermore, the mean number of exacerbations was 2.8 (SD 2.7; median 2) and 1.5 (SD 1.9; median 1) per patient during oneyear follow-up in the intervention and usual care group, respectively. The majority (69%) of all exacerbations in the intervention group were self-treated at home, resulting in a 42% reduction in doctor consultations per patient per year compared to the usual care group. This paper reports the economic evaluation of the COPE self-management programme. As the clinical evaluation did not show significant effects on HRQoL, we did not expect substantial differences in QALYs, the focus of this analysis was to investigate whether a comprehensive self-management programme is an efficient treatment option for moderate to severe COPD patients compared to usual care as provided by secondary care chest physicians.
Methods
All COPD patients were recruited from one outpatient pulmonary clinic and were aged between 40 and 75 years. The diagnosis of COPD was confirmed by spirometry (ratio of FEV1 to FVC <60%, FEV1 percent predicted < 80%) and absence of a bronchodilator response (AFEV1% predicted following inhalation of 80 mcg of ipratropium bromide < 12%).8
Patients were excluded if they had asthma as pnrmary Chrorc Rsjpratory Disese diagnosis. Detailed in, and exclusion criteria of, the COPE study have been described previously.9
Study design
The overall COPE study was divided into two substudies. During the first substudy (discontinuation of Inhaled Corticosteroids (ICS) study),9 the lung function of patients was optimized including a fourmonth regimen of fluticasone propionate 500 Htg twice daily, broncho-dilation, and a smoking cessation programme for current smokers.10 All patients were instructed in the correct use of their inhaled medication. After these four months, patients were randomly assigned to continue fluticasone propionate 500 p g twice daily or to receive placebo for six months. After the first substudy, all patients entered the second substudy (the COPE self-management study) and were randomized once more into an intervention group receiving a comprehensive self-management programme and a usual care group.
The COPE self-management intervention consisted of three elements: 1) A self-management education course, supplemented by a specially made booklet with background information on COPD and the content of the education course. The self-management education course was primarily designed to achieve behavioural change and to acquire self-management skills using the Attitude, Social Support and Selfefficacy (ASE) model as theoretical concept.11 The course consisted of five two-hour group sessions. Four sessions were given with a one-week interval and the last (feedback) session was given three months after the fourth session. The first session addressed coping with breathlessness, obtaining better insight into the nature of the disease, symptom perception, and coping with triggers for breathlessness. During the second session the importance of exercise and relaxation were emphasized. Patients were motivated to participate in the fitness programme. Furthermore, attention was paid to ergonomic posture and energy conservation during daily activities or work. The third session concentrated on nutrition and its implications for COPD patients. The risk of involuntary weight loss was emphasized. The themes of the fourth session were communication and social relationships. Changing role patterns and communication with the chest physician and other health-care professionals were stressed. The feedback session was aimed at Economic evaluation of the COPE self-management study E Monninkhof et al. 9 exchanging experiences and maintaining the acquired knowledge and skills. 2) A fitness programme, which consisted of one or two one-hour small group training sessions per week for the duration of the study (two years) under guidance of a physiotherapist trained in COPD care. The programme included strength training, breathing and cardiovascular exercises and besides physical goals, the fitness programme was aimed at coping with the disease, recognizing their individual capacity, social interactions and behavioural change. If possible, patients were referred to a physiotherapist stationed in their neighbourhood in order to facilitate participation and to increase social interaction with other patients in the same geographical area. 3) Guidelines for self-treatment of exacerbations.
These guidelines were based on symptom perception and were introduced during the first education session. In order to be able to interpret and use these guidelines properly, they were discussed again each session. If patients experienced an increase of respiratory symptoms and normally would have called their physician, they could initiate treatment with a short course of oral steroids, if necessary complemented with antibiotics.
Patients in the control group received usual care from their chest physician. Pharmacological treatment of exacerbations was standardized as much as possible. In order to obtain valid data about exacerbations, this group of patients was instructed to call the COPE study office if they felt in need of assistance for a worsening of their respiratory symptoms, and they would normally have called their chest physician or GP instead. At the COPE office, the data managers dealt with all telephone calls first. A physician subsequently offered treatment advice by telephone or invited the patient to come to the hospital for consultation. Patients in the intervention group were instructed to contact the COPE office in case of doubt, a fast deterioration of their pulmonary condition, or absence of improvement by self-treatment of an exacerbation. Subsequently, the same procedure as in the usual care group was followed. Treatment of exacerbations was standardized to a short course of oral corticosteroids of 30 mg prednisolone for a period of 10 days and, when necessary, antibiotics. First choice of antibiotics was amoxicillin/ clavulanic acid 625 mg four times daily for a period of 10 days. Second choice was doxycycline 100 mg daily for a period of 10 days. Patients in the self-management group had prescriptions or medication at home.
Outcomes
Primary outcome for the base-case analysis (primary analysis) was defined in terms of quality-adjusted life years (QALYs). The number of QALYs is derived by the adjustment of survival data for community-based utilities. Weights for these utilities were obtained from the EuroQol-5D questionnaire,12 which provides a descriptive profile and a utility. This questionnaire includes five dimensions (mobility, self-care, daily activities, pain and mood). A higher utility means a better health status and the maximum score is 1 (best imaginable health state).
We also measured disease-specific HRQoL by means of the Dutch version of the St George's Respiratory Questionnaire (SGRQ).7 The SGRQ is composed of 76 items that are weighted to produce scores in three domains and a total score. Scores range from 0 to 100, with lower scores indicating better health status. A change of score of four points is considered to be clinically significant.'33,4
Economic evaluation A decision analytic model was developed to evaluate the (incremental) costs of the self-management and usual care strategies. Figure 1 depicts the decision analytic model and the base-case probabilities for each step in the model.
A base-case cost-utility analysis was uerformed according to the US panel on CEA guideline. 5-17 This analysis took the societal perspective and the time perspective was one year. The base-case analysis incorporated assumptions based on the clinical evaluation of the COPE self-management trial (Figure 1 ).
One-way sensitivity analyses were performed to evaluate the relative impact of the various parameters in the analysis. Cost components were varied over a range of 50-150% of the actual cost. The probabilities of experiencing at least one exacerbation in both groups were varied between the lower and upper 95% confidence limits. Probabilities of a limited activity day, a hospital admission, and the mean number of exacerbations per patient were varied over clinically meaningful ranges. Furthermore, we performed an analysis excluding indirect costs and an analysis setting the time costs for the fitness programme to zero. The latter was induced by the notion that patients could value time spent exercising equivalent to time spent in other leisure activities.5 A Monte Carlo simulation (@Risk 3.5 software) with 1000 iterations was carried out to explore the variation in the incremental costs when cost parameters wmm.CRquml.com Economic evaluation of the COPE self-management study E Monninkhof et al.
10 Figure 1 Decision tree depicting the self-management and usual care strategies and the base-case probabilities for each transition. Furthermore, the base-case analysis incorporated the following assumptions derived from the clinical evaluation of the COPE study: 1) the probability to participate in the fitness programme is 0.77; 2) the probabilities of an outpatient visit, telephone consultation and general practitioner (GP) visit for an exacerbation (excluding self-treated exacerbations and hospitalizations) in the self-management group were 0.37, 0.33 and 0.30, respectively; in the usual care group, these probabilities were 0.43, 0.33 and 0.24; 3) the mean number of exacerbations was 2.8 in the self-management group and 1.5 in the usual care group.
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Economic evaluation of the COPE self-management study E Monninkhof et al. 11 and probabilities were varied simultaneously over their ranges and associated 95% CI, respectively. For costs, a triangular distribution was used, and a logistic-normal distribution was used for all probabilities.'8 For the mean number of exacerbations, we used a normal distribution.
Measurement of resource utilization
Resource use was measured in natural units and was valued in monetary terms by multiplying these units by the costs per unit. Costs were distinguished into programme costs, direct medical costs, direct nonmedical (travel) costs and indirect costs. The number of programme-related physiotherapy visits of each patient in the intervention group was prospectively recorded by the physiotherapists. Data on health-care resource utilization associated with COPD exacerbations were prospectively recorded during the study by active follow-up of the patients' records, both inpatient and outpatient, with regard to hospitalizations, scheduled and emergency outpatient visits. We also contacted all the patients' general practitioners (GPs) to enquire about treated exacerbations. The treating physician recorded treatment of exacerbations with prednisolone and antibiotics in a standardized report form. In case of self-treated exacerbations, patients also recorded the use prednisolone and antibiotics in a two-week diary and in a standardized report form. Additionally, pharmacists reported all drugs delivered during the study period. Standard values for travel distances to the hospital, GP and physiotherapist as specified by current Dutch guidelines on good pharmaco-economic practice were used. 9 Indirect costs were defined as lost productivity during usual daily activities caused by exacerbations and time costs borne by the individual. Patients recorded time lost from usual daily activities (i.e. housekeeping) and paid employment because of exacerbations in a standardized report form. Mean patient time required for the self-management education course, a physiotherapy visit and an unscheduled emergency outpatient visit were estimated at 15, 1.5 and 2.5 hours (including waiting and travel time), respectively.
Resource valuation
Standard cost prices as specified by current Dutch guidelines on good pharmaco-economic practice were the first-choice source for resource unit valuation. 19 Also, lost productivity during usual daily activities due to exacerbations and time spent in the self-management education course and fitness programme was valued according to these guidelines (E8 per hour). As only 18% of our population were in paid employment, we used this price to convert all limited activity days (eight-hour workday) into monetary terms regardless of employment status or income of individual participants. Medication costs for exacerbations were based on market prices for dispensed medication and included pharmacy cost. The costs of self-management education included salary costs of the respiratory nurses, travel and parking costs, time costs, costs of the selfmanagement booklet and rent for office space. The cost of the different unscheduled health-care contacts (outpatient, telephone consultation, GP visits) included salary, travel, parking and time costs, if applicable. Costs of daily medication use and scheduled outpatient visits were excluded from the base-case analysis, because these were equally divided in both groups.
Costs were based on 2002 unit prices in the Netherlands. For conversion to US dollars, costs in euros should be multiplied by a factor of 0.934, based on the 2002 Purchasing Power Parities as issued by the Organization for Economic Co-operation and Development (www.oecd.org).
Owing to the short time perspective, costs and effects were not discounted for time preferences.
Statistical analysis
An intent-to-treat analysis was performed, including all randomized subjects regardless of their compliance. Within and between group differences in EuroQol utility score and SGRQ total score were assessed b analysis of repeated measurements using Proc Mixed (mixed models approach) from SAS and 95% CI were calculated.
Quality-adjusted life years were determined by calculating the area under the curve (time x utility score) for each participant. Mean differences in QALYs were tested using t-test statistics.
Results

Patients and QALYs
In total, 248 moderate to severe COPD patients were randomly allocated to either the self-management (127) or usual care (121) group. Treatment groups were similar with respect to the known prognostic variables. In the self-management group five patients (three deaths, two other) dropped out, as did seven patients (three deaths, two carcinoma, two other) in the usual care group. Thus, 122 patients in the self-management and 114 in the usual care group completed the one-year follow-up. Table 1 shows the baseline characteristics of both treatment groups. aAll variables were measured at baseline unless otherwise stated.
Mean values were based on 122 and 118 patients in the intervention and usual care group, respectively.
Repeated measurement analysis did not reveal differences within and between treatment groups in mean utility score measured by the EuroQol-5D and HRQoL measured by the SGRQ ( Table 2 ). The mean number of QALYs standardized to one-year follow-up were equal in both treatment groups: 0.81 (SD 0.17) and 0.81 (SD 0. 19). As we did not find any difference in QALYs between groups and no cost-effectiveness ratios can be calculated, we will describe a cost-analysis only.
Cost-analysis
The self-management programme specific costs amounted to 4642 per patient ( Table 3 ). Physiotherapist visits and patient time costs (for the education course and fitness programme) constituted the major part of the programme specific costs (17 and 65%, respectively). The probability of using antibiotics for an exacerbation was 0.59 in the self-management group and 0.57 in the usual care group. Mean cost for an exacerbation was 431.42 in the self-management group and C30.66 in the usual care group. The average number of limited activity days during exacerbation recovery was 4.1 (SD 4.2) in the self-management group and 5.3 (SD 5.3) in the usual care group: the associated mean indirect cost per patient per exacerbation was C337 and C436, respectively. The average number of hospital days was 11.4 (SD 6.0) days for both groups. There were no admissions on the intensive care unit. The mean cost for a hospital stay including patient time was C375 1.
In the base-case cost analysis, the total annual costs were substantially higher for patients in the selfmanagement group than for patients in the usual care group (' 1643 vs. 805), largely because of cost incurred by the programme itself. So, the associated incremental costs amounted to 838 per patient per year in favour of usual care ( Table 4 ). The incremental costs of self-management relative to usual care for direct medical care alone were 179 per person per year. When productivity costs were excluded, the incremental annual costs of self-management relative to usual care were 193 per person per year.
Sensitivity analysis
Based on univariate sensitivity analysis, the results from the cost minimization analysis were not sensitive to realistic changes in the assumptions upon which they were based. Varying the probability of a hospitalization, a limited activity day, the costs of a limited activity day and time costs did not alter the treatment decision, but these parameters influenced the cost difference most (Table 5 ). If time costs for the fitness programme were set to zero, the incremental costs for self-management were reduced to E542 per person per year. Figure 2 shows the results of the Monte Carlo simulation on cost per exacerbation difference. Mean incremental costs for the self-management strategy were E828 (interquartile range E632-1037). In only 12.4% of all simulations, the extra costs for the self-management strategy were CSource used for unit valuation: retail prices. dSource used for unit valuation: standard cost prices as specified by current Dutch guidelines on good pharmaco-economic practice.'9 eSource for unit valuation: based on actual cost in our hospital.
offset by a reduction in the mean number of exacerbations compared to the usual care group.
Discussion
This economic evaluation showed that the COPE selfmanagement programme is not a cost-efficient treatment option for moderate to severe COPD patients with regard to improving HRQoL. The programme was twice as expensive as usual care (E1643 vs. 805) and had no measurable beneficial effects on HRQoL. The majority of the difference in societal costs could be attributed to the costs for the self-management education course and the weekly fitness training. If only direct medical costs were included, the incre- mental costs for self-man gement relative to usual care reduced significantly to 179 per patient per year. As we take into account the cost for regular prescription medication and the scheduled physician visits, the costs generated by the usual care group will be slightly higher than the mean annual costs for COPD ( 1024) estimated by the Confronting COPD survey in the Netherlands. 20 The more severe outpatient COPD bThis probability is based on patients with at least one exacerbation.
CVaried over the probability range from 0 to 0.5. The probability of 0.5 is based on the probability of at least one hospitalization for an exacerbation in the usual care arm of the Bourbeau study.29 dCosts varied from 50 to 150%. eTime costs for the self-management education course and fitness programme (opportunity costs of leisure).
Economic evaluation of the COPE self-management study E Monninkhof et al. 14 Figure 2 Results of a Monte Carlo simulation on cost per exacerbation difference. A negative -amount favours the usual care strategy. A positive difference in number of exacerbations favours the usual care strategy. population can explain the slightly higher annual costs per patient in our study. So, we are confident that our study population resembles the general COPD outpatient population in the Netherlands.
Patient time costs for the fitness programme constituted about one-third of the incremental costs of a self-management patient. Inclusion of time costs and valuation of these costs led to much discussion among health economists.5,21 We did not measure how individuals value the time spent in the fitness programme. If patients value time spent exercising equivalent to time spent in other leisure activities, then the time cost should be valued as zero.5 As the results of a qualitative study22 indicate that our patients were very enthusiastic about the fitness programme and attendance to the programme was voluntary, we feel that neglecting these time costs might be justified. The sensitivity analysis revealed that if time costs for the fitness programme were set to zero, the opportunity costs for self-management diminished (C542).
In COPD, we are aware of one other randomized controlled trial analysing the costs and cost-effectiveness of self-management in patients with COPD.23 This study (the Gallefoss study) concluded that patient education reduced costs and improved outcomes. The relevance of the selected effectiveness measures, that is, a GP independent patient, satisfaction with GP care, and reduced use of rescue medication might be Chronc Reoratory Dsease discussed. The cost savings ($1329 in 1994) in the Gallefoss study are in contrast to the expenses in our study. This might partly be explained by the fact that reduced absenteeism from work (48%, n = 27, was employed) explained most of the difference in total costs. These results should be considered in the light of small numbers and skewed cost distribution: only three out of 14 and two out of 13 in the intervention and usual care group respectively, reported on absence from work. So, the two patients reporting absence from work in the usual care group were major cost drivers due to a high number of lost productivity days. A limitation of our study is that we did not collect productivity data in stable state. If we assume that our self-management group experienced less limited activity days beyond exacerbation periods than the usual care group, that is, because of increased exercise capacity or better coping behaviour, the cost difference between the groups will diminish.
Another explanation for the expenses in our study is the two-fold higher exacerbation frequency in the selfmanagement group (due to self-treatment) compared to usual care. The reduced number of health-care contacts for exacerbations did not outweigh the increased medication costs for exacerbations. As it is very unlikely that the difference in exacerbation frequency is a real effect of participating in the self-management programme, the question remains whether the difference in reported exacerbation frequency was induced by underreporting in the usual care group or overreporting and thus overtreatment in the self-management group. If the latter is the case, future self-management programmes should probably incorporate more individualized selftreatment action plans, so the medication costs and potential side effects of self-treatment will diminish. 24 Since studies have shown that in developed countries the primary cost driver for COPD is hospital care for exacerbations, [25] [26] [27] [28] prevention of hospitalization is an important outcome in economic studies in COPD. However, in our fairly well stabilized moderate to severe COPD population, the number of hospitalizations was small and no ICU admissions were necessary. So, the room for subsequent cost savings by preventing hospitalizations due to the self-management programme is limited. A self-management programme including more severe COPD patients might yield savings in hospitalization costs. A self-management study of Bourbeau et al. found a 40% reduction in hospital admissions for exacerbations in a group of more severe and less stable COPD patients, already admitted once before entering this study. 29 Another limitation of this evaluation is the relatively short time horizon, since some study effects might change during longer follow-up. For example, excessive self-treatment might fade out when patients gain more experience in self-treatment. Furthermore, the difference in limited activity days and hospitalizations might become more pronounced.
Although we did not find differences on HRQoL and QALYs, we are not willing to conclude that the selfmanagement programme had no beneficial effects on patients' well-being. To understand the striking discrepancy between subjective positive signals of the self-management patients and the objective HRQoL data in the COPE study, we have performed a qualitative study.22 This qualitative study indicated several positive effects of the self-management programme on exercise capacity, symptom control, coping behaviour, disease-specific self-confidence, and acceptation of energy conservation measures. The qualitative interviews suggest that the SGRQ and possibly other existing HRQoL instruments might fail to capture the full experience of patients in self-management studies.
The final point of discussion is whether selfmanagement programmes for COPD patients in general will be a future treatment option, taking in consideration health effects and costs. In COPD, several studies on the efficacy of self-management education have 30 been published. A recent Cochrane Review, including eight studies of self-management education for patients with COPD, concluded that the available evidence is inconclusive due to different study designs, methodo-logical limitations, and a wide variation in reported outcome measures. The Bourbeau study,29 published after the Cochrane Review, reported a reduction of exacerbations (18%), emergency room visits (41%), unscheduled physician visits (60%), and hospitalizations for exacerbations (40%) in the self-management group. The Bourbeau study found a between-group difference in HRQoL at four months follow-up; however, only a marginal effect in HRQoL, and only on the impact subscale, was observed at 12 months. The most important difference between the Bourbeau study and our study, which might explain the strikingly different results, is the severity of COPD. Although both studies selected patients in GOLD stage II, our study population had much milder disease as reflected by a relatively high rating of their HRQoL and a lower exacerbation rate pre-trial.
Taking into account the negative results from our study and the positive results from the Bourbeau study in relation to the results of the Cochrane Review, we are still unable to pronounce sentence upon the (cost)effectiveness of self-management programmes in COPD in general.
In conclusion, the COPE study has not been able to show cost-effectiveness of a comprehensive selfmanagement programme in moderate to severe COPD patients who rate their HRQoL relatively highly. Future self-management studies should include more severely impaired COPD patients since there are indications for beneficial effects in this subgroup of patients.
